KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively ...
Those uninterested in the specialty report concerns about compensation, training length, and limited procedural opportunities ...
Consolidated Sales of $157.6 million, down 1% excluding foreign exchangeNet Income of $5.8 million and EBITDA of $18.0 million;Earnings per Share of $0.15, including $0.06 per share in restructuring ...
The findings underscore the potential consequences of the continued slide in vaccine uptake, such as increased healthcare ...
The International Criminal Court on Tuesday ordered an al-Qaida-linked extremist leader to pay 7.2 million euros ($8.4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results